ClinicalTrials.gg
RecruitingNCT07259252InVaACSUpdated Jan 13, 2026

Influenza Vaccination After Acute Coronary Syndrome

An interventional study of Influenza vaccine and Placebo in Acute Coronary Syndromes (ACS), sponsored by Tongji Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Tongji Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,620
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Acute Coronary Syndrome with a site in China — 55 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
12th of 115
6,620 · median 499
Started
2025
with 14 others
No phase
47 of 185
20 open now
Primary completion
2029-03
later than 60 of 62 live
Registered
171st of 185
by date

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 12th largest by planned enrollment of the 115 interventional ones that give a count, is one of 15 that started in 2025, is one of 47 with no phase, reaches primary completion later than 60 of the 62 other live ones, and was the 171st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

55 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

49 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are:

  • Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke?
  • Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, stent thrombosis?

If there is a comparison group: Researchers will compare influenza vaccination and placebo to see if adverse cardiac events decrease.

Participants will receive an influenza vaccination or placebo after enrollment and phone calls for follow-up at 1 month, 3 months, 6 months and 1 year after discharge.

03

Conditions studied

  • Acute Coronary Syndromes (ACS)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ACS patient aged from 18 to 80 years.
  2. Volunteer for the study and written .

Exclusion criteria

Exclusion Criteria:

  1. Participate in any drug clinical trials within 3 months.
  2. Patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years.
  3. Serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients).
  4. Previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix).
  5. Patients refused to comply with the requirements of this study to complete the research work.
  6. Patients Received influenza vaccination within 1 year.
  7. Patients with for influenza vaccination.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
6,620 participants (estimated)

Study arms

  • Experimental
    influenza vaccination

    patients will receive influenza vaccination

    Drug: Influenza vaccine

  • Placebo comparator
    placebo

    patients will receive placebo (PBS)

    Drug: Placebo

Interventions

  • DrugInfluenza vaccine

    Patients receive injection of 0.5ml influenza vaccine

  • DrugPlacebo

    Patients will receive injection of 0.5ml PBS

06

What researchers measure

Primary outcomes

  1. Composite endpoint of cardiovascular death, myocardial infarction or stroke

    The number of participants with cardiovascular death, myocardial infarction or stroke (first occurring) till 12 months.

    Time frame: 12 months

Secondary outcomes

  1. all cause death

    The number of participants with all cause death till 12 months

    Time frame: 12 months

  2. cardiovascular death

    The number of participants with cardiovascular death till 12 months

    Time frame: 12 months

  3. stroke

    The number of participants with stroke till 12 months

    Time frame: 12 months

  4. myocardial infarction

    The number of participants with myocardial infarction till 12 months

    Time frame: 12 months

  5. unplanned hospitalization for heart failure or for arrhythmia

    The number of participants with unplanned hospitalization for heart failure or for arrhythmia till 12 months

    Time frame: 12 months

  6. unplanned revascularization

    The number of participants with unplanned revascularization till 12 months

    Time frame: 12 months

  7. stent thrombosis

    The number of participants with stent thrombosis till 12 months

    Time frame: 12 months

Other outcomes

  1. influenza like illness

    The number of participants with fever (body temperature ≥38℃) accompanied by cough or sore throat till 12 months

    Time frame: 12 months

  2. hospitalization for influenza

    The number of participants with hospitalization for influenza till 12 months

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
    • Yang Sun, MD · Contactsunyang.7@163.com · 86-15527674573
    • Dao Wen Wang, MD, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Mar 2029, 39 months after the start.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 39 months is above that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartActual
Dec 3, 2025
Primary completionEst.
Mar 30, 2029
CompletionEst.
Mar 30, 2029
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259252
Lead sponsor
Tongji Hospital
Responsible party
Dao Wen Wang (Professor, Tongji Hospital) — Principal investigator
First posted
Dec 2, 2025
Start date
Dec 3, 2025
Primary completion
Mar 30, 2029 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Jan 13, 2026

Study contacts

Yang Sun
Contact
sunyang.7@163.com
+86-15527674573
Dao Wen Wang
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion